Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, et al
Tesamorelin Tesamorelin specifically reduces visceral fat, or fat thats held deep in the abdomen
The phase 3 TRIUMPH-4 data showed these rates at 9 mg and 12 mg doses respectively: Nausea: 38.1% and 43.2% (vs 10.7% placebo) Diarrhea: 34.7% and 33.1% (vs 13.4% placebo) Constipation: 21.8% and 25.0% (vs 8.7% placebo) Vomiting: 20.4% and 20.9% (vs placebo) These numbers are higher than cagrilintide monotherapy across the board
Protects against Premature Aging: It's also like a superhero shield, protecting our Skin from environmental factors, including pollution and harsh sunlight.
BMJ 372 , n436 (2021)
The consumer was prohibited from suing the manufacturer because the consumer didnt have a contract with the manufacturer